Exelixis Stock Jumps Nearly 9% On Positive Phase 3 Colorectal Cancer Trial Results

(RTTNews) - Exelixis, Inc. (EXEL) is trading at $43.77, up 8.41 percent, or $3.40 on Monday, after the company announced positive topline results from its Phase 3 STELLAR-303 trial in metastatic colorectal cancer.

The stock opened at $49.36 and has traded between $43.03 and $49.40 so far today. Volume has surged to 6.82 million shares, well above the average of 2.97 million. Exelixis shares have ranged between $21.82 and $49.40 over the past 52 weeks.

The study showed that its investigational drug Zanzalintinib, combined with Genentech's Tecentriq, significantly improved overall survival compared to Bayer's Regorafenib in previously treated patients.

)